Vitrectomy outcomes are affected by retinoschisis in myopic macular holes

Article

Vitrectomy used to treat highly myopic macula holes (HMMHs) is negatively affected by retinoschisis.

Vitrectomy used to treat highly myopic macula holes (HMMHs) is negatively affected by retinoschisis, claims a study in the British Journal of Ophthalmology.

Dr Yasushi Ikuno et al., Department of Ophthalmology, Osaka University Medical School, Yamadaoka, Japan, performed a retrospective cross-sectional study on 22 eyes with HMMHs that underwent vitrectomy.

All eyes were split into two groups. Ten eyes were identified with retinoschisis and 12 did not have retinoschisis. Posterior staphyloma height was measured by optical coherence tomography (OCT). The surgical outcomes were postoperative final best-corrected visual acuity (BCVA) and reoperation rate.

Postoperative BCVA was strongly linked to presence or absence of retinoschisis and preoperative BCVA. The schisis group presented with a worse visual acuity and a greater posterior staphyloma height than the non-schisis group.

Highly myopic eyes presented with two types of macula holes with significantly different prognosis. The investigation suggests the careful interpretation of preoperative OCT images to identify accurate surgical results.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.